In the BioHarmony Drug Report Database

"Preview" Icon

Telbivudine

Tyzeka (telbivudine) is a small molecule pharmaceutical. Telbivudine was first approved as Tyzeka on 2006-10-25. It is used to treat chronic hepatitis b and hepatitis b in the USA. Sebivo, tyzeka’s patent is valid until 2023-09-11 (FDA).

 

Trade Name

 

Tyzeka
 

Common Name

 

telbivudine
 

ChEMBL ID

 

CHEMBL374731
 

Indication

 

chronic hepatitis b, hepatitis b
 

Drug Class

 

Antineoplastics,antivirals (zidovudine group) (exception: edoxudine)

Image (chem structure or protein)

Telbivudine structure rendering